Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0004623 (
bacterial infection
)
15,226
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Enteropathogenic Escherichia coli (EPEC) is an important cause of
infant diarrhea
in developing countries and is useful for general investigations of the
bacterial infection
process. However, the study of the molecular pathogenesis of EPEC has been hampered by the lack of genetically tractable, convenient animal models. We have therefore developed the use of the nematode Caenorhabditis elegans as a small animal model of infection for this diarrheal pathogen. We found that nematodes died faster on nematode growth medium in the presence of EPEC pathogens than in the presence of the laboratory control strain MG1655. Increased numbers of pathogens in the gut, determined by standard plate count assays and fluorescence microscopy using green fluorescent protein-expressing bacteria, correlated with killing. Deletion of the gene encoding the global regulator Ler severely reduced the ability of EPEC to colonize the nematode gut and could be complemented by providing the ler gene on a multicopy plasmid in trans. Neither the type III secretion system nor the type IV bundle-forming pilus was required for colonization. Combined, the similarities and distinct differences between EPEC infection of nematodes and that of humans offer a unique opportunity to study several stages of the infection process, namely, attachment, colonization, and persistence, in a genetically tractable, inexpensive, and convenient in vivo system.
...
PMID:The global regulator Ler is necessary for enteropathogenic Escherichia coli colonization of Caenorhabditis elegans. 1636 58
We investigated the
in vitro
effects of
Lactobacillus casei
ZX633 on gut microorganism composition in infants with diarrhea. For this purpose, 103 feces samples from healthy infants (healthy group) and 300 diarrhea samples from infants (diarrhea group) were collected, and diarrhea feces were treated with
L. casei
ZX633, which was previously isolated from healthy infant feces (treatment group). We used microbial dilution plate methods, high performance liquid chromatography (HPLC) and high-throughput sequencing approaches to analyze viable main microorganism counts, short chain fatty acid (SCFA) concentrations, and intestinal microbiota composition in feces, respectively. Our data showed that
L. casei
ZX633 supplementation increased the numbers of
Escherichia coli
, yeasts, lactic acid bacteria (LAB) and aerobic-bacteria, raised propionic acid levels but reduced four other SCFAs, which are close to the healthy group. Alpha diversity results indicated that microbial diversity and richness decreased in treatment group. Bacterial community analyses revealed that microbial structures of the treatment group tended toward the healthy group; i.e.,
Escherichia-Shigella
and
Clostridioides
abundance increased, and there was a reduction in the abundance of
Streptococcus, Bacteroides, Enterococcus
and
Veillonella
. In conclusion,
L. casei
ZX633 isolated from healthy infant feces, may be effective in improving
infant diarrhea
microbiota, potentially providing a new probiotic strain to reduce the incidence of diarrhea associated with
bacterial disease
in infants.
...
PMID:The
in vitro
Effects of the Probiotic Strain,
Lactobacillus casei
ZX633 on Gut Microbiota Composition in Infants With Diarrhea. 3307 28
